SAN FRANCISCO, CA—After decades of research aiming to understand how DNA is organized in human cells, scientists at the Gladstone Institutes have shed new light on this mysterious field by discovering how a key protein helps control gene organization.
SAN FRANCISCO, CA—A team of researchers at the Gladstone Institutes uncovered a new strategy to treat heart failure, a leading contributor to mortality and healthcare costs in the United States.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes created a special type of neuron from human stem cells that could potentially repair spinal cord injuries. These cells, called V2a interneurons, transmit signals in the spinal cord to help control movement.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes identified an FDA-approved drug that can create the elusive and beneficial brown fat. Mice treated with the drug had more brown fat, faster metabolisms, and less body weight gain, even after being fed a high-calorie diet.
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes linked a single gene mutation to two types of heart disease: one causes a hole in the heart of infants, and the other causes heart failure.
SAN FRANCISCO, CA—A new biopharmaceutical company, Tenaya Therapeutics Inc., will build on discoveries in cardiovascular disease research made at the Gladstone Institutes, concentrating on regenerative medicine and drug discovery fo
SAN FRANCISCO, CA—Scientists at the Gladstone Institutes identified two chemicals that improve their ability to transform scar tissue in a heart into healthy, beating heart muscle. The new discovery advances efforts to find new and effective treatments for heart failure.
SAN FRANCISCO, CA—How do you improve a Nobel Prize-winning discovery? Add a debilitating disease-causing gene mutation.
SAN FRANCISCO, CA—Stem cell experts will discuss the future of cellular reprogramming and its therapeutic potential at the Cell Symposium “10 Years of iPSCs,” September 25–27, 2016 at the Claremont Hotel and Spa in Berkeley, Califo
SAN FRANCISCO, CA—With a trick of engineering, scientists at the Gladstone Institutes improved a potential weapon against inflammation and autoimmune disorders. Their work could one day benefit patients who suffer from inflammatory bowel disease or organ transplant rejection.